Log In
Print
BCIQ
Print
Print this Print this
 

namilumab (MT203)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb that neutralizes the proinflammatory cytokine granulocyte macrophage colony-stimulating factor (GM-CSF)
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)
Mechanism of ActionGranulocyte macrophage colony stimulating factor (GM-CSF) receptor antagonist
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner

Takeda Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today